Dr. Hofmeister on Reolysin Combined With Carfilzomib for Multiple Myeloma

Craig Hofmeister, MD
Published: Monday, Jan 04, 2016



Craig Hofmeister, MD, assistant professor of Internal Medicine, Division of Hematology, Department of Internal Medicine, Ohio State University, discusses a study that examined the efficacy of reolysin combined with carfilzomib in patients with relapsed multiple myeloma.

This phase I dose-escalation study examined the relapsed population, as well as some patients who were refractory to carfilzomib, Hofmeister explains. A total of 12 patients received the combination of reolysin, an oncolytic virus, and carfilzomib at two different levels.

At the starting dose level, all patients responded to the regimen; 6 patients were able to remain on therapy without disease progression. At a decreased dose, the majority of patients did not respond to the combination, which was an unexpected result, Hofmeister says.



Craig Hofmeister, MD, assistant professor of Internal Medicine, Division of Hematology, Department of Internal Medicine, Ohio State University, discusses a study that examined the efficacy of reolysin combined with carfilzomib in patients with relapsed multiple myeloma.

This phase I dose-escalation study examined the relapsed population, as well as some patients who were refractory to carfilzomib, Hofmeister explains. A total of 12 patients received the combination of reolysin, an oncolytic virus, and carfilzomib at two different levels.

At the starting dose level, all patients responded to the regimen; 6 patients were able to remain on therapy without disease progression. At a decreased dose, the majority of patients did not respond to the combination, which was an unexpected result, Hofmeister says.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x